C4.4A protein is a glycosylphosphatidylinoditol (GPI)-binding protein encoded by the LYPD3 gene in humans. It contains two urokinase-type plasminogen activator receptor (uPAR) domains and belongs to the Ly6/uPAR/alpha-neurotoxin (LU) domain family. C4.4A was originally identified in studies of rat pancreatic cancer and urothelial cancer. It is expressed in squamous epithelial cells, mostly in esophagus and skin, and in the amnion membrane in placenta. In humans, C4.4A expression has been reported in malignant melanoma, and urothelial, lung, esophageal, and colon cancers. C4.4A is also known as LY6/PLAUR domain containing 3 (LYPD3), matrigel-induced gene C4 protein (MIG-C4), and GPI-anchored metastasis-associated protein C4.4A homolog.
This product is an affinity-purified IgG antibody that recognizes human C4.4A/LYPD3 protein. The antibody was raised in rabbit using a synthetic peptide and can be used for Western blot (WB) detection or immunohistochemical (IHC) detection of human C4.4A/LYPD3 protein.